Loading...
XSTO
XVIVO
Market cap623mUSD
Dec 05, Last price  
185.70SEK
1D
3.80%
1Q
9.49%
Jan 2017
111.02%
IPO
805.85%
Name

Xvivo Perfusion AB

Chart & Performance

D1W1MN
XSTO:XVIVO chart
P/E
33.97
P/S
7.11
EPS
5.47
Div Yield, %
Shrs. gr., 5y
3.39%
Rev. gr., 5y
30.08%
Revenues
822m
+37.63%
14,724,00068,922,00084,702,000120,245,000138,177,000148,342,000187,868,000220,838,000179,861,000258,386,000415,292,000597,542,000822,415,000
Net income
172m
+87.52%
-769,0008,054,0003,738,0005,131,0001,501,0006,260,00012,685,0004,939,000-43,735,0008,152,00018,427,00091,820,000172,182,000
CFO
111m
+140.43%
1,669,00013,464,000-3,741,0008,578,00012,550,00022,190,00023,627,00029,505,000-12,266,000-12,059,00027,856,00046,287,000111,290,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
IPO date
Oct 08, 2012
Employees
142
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT